Sodium/glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of both cardiovascular death and hospitalization for HF in patients with HF, regardless of diabetes mellitus7–11. This evidence concerns the gene SLC5A2 and hydrops fetalis.